Observational studyDiabetologia2016
Death, end-stage renal disease and renal function decline in patients with diabetic nephropathy in French cohorts of type 1 and type 2 diabetes.
Observational study in Diabetologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Comprehensive Factors for Predicting the Complications of DiabetesMellitus: A Systematic Review.Current diabetes reviews · 2024Pooled it
- Association between AGTR1 A1166C polymorphism and the susceptibility to diabetic nephropathy: Evidence from a meta-analysis.Medicine · 2018Pooled it
- Novel risk genes identified in a genome-wide association study for coronary artery disease in patients with type 1 diabetes.Cardiovascular diabetology · 2018Pooled it
- The effect of linagliptin on microalbuminuria in patients with diabetic nephropathy: a randomized, double blinded clinical trial.Scientific reports · 2023Trial
- Article
- Renoprotective Action of Linagliptin Among Diabetic Kidney Disease Patients: A Systematic Review and Meta-Analysis.Cureus · 2025Review
- Asiaticoside improves diabetic nephropathy by reducing inflammation, oxidative stress, and fibrosis: AnWorld journal of diabetes · 2024Article
- The role of innate immunity in diabetic nephropathy and their therapeutic consequences.Journal of pharmaceutical analysis · 2024Review
- GLP-1 Receptor Agonist Improves Mitochondrial Energy Status and Attenuates Nephrotoxicity In Vivo and In Vitro.Metabolites · 2023Article
- Multifaceted relationship between diabetes and kidney diseases: Beyond diabetes.World journal of diabetes · 2023Review
- Article
- Gut microbiota dysbiosis as an inflammaging condition that regulates obesity-related retinopathy and nephropathy.Frontiers in microbiology · 2022Article
- Roles and crosstalks of macrophages in diabetic nephropathy.Frontiers in immunology · 2022Review
- Baicalin reversal of DNA hypermethylation-associated Klotho suppression ameliorates renal injury in type 1 diabetic mouse model.Cell cycle (Georgetown, Tex.) · 2020Article
- Impact of Liver Cirrhosis on Incidence of Dialysis Among Patients with Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Article
- Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis.Stem cell research & therapy · 2020Article
- Evaluation of mortality risk factors in diabetic foot infections.International wound journal · 2020Article
- Article
- Renal Complication and Glycemic Control in Korean Veterans with Type 2 Diabetes: A 10-Year Retrospective Cohort Study.Journal of diabetes research · 2020Article
- Significance of Microalbuminuria in Predicting Silent Myocardial Ischemia in Patients with Type 2 Diabetes Using Myocardial Perfusion ImagingMolecular imaging and radionuclide therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisMicrovascular complications are a common feature of diabetes but additional research is needed regarding diabetic nephropathy endpoints in type 1 and type 2 diabetes.
methodsWe compared 277 type 1 diabetes patients with 942 type 2 diabetes patients, with clinical proteinuria and no endstage renal disease (ESRD) at baseline, prospectively followed for death, ESRD and decline in estimated glomerular filtration rate (eGFR, all available measures).
resultsThe incidence rate of death was 67.0 (95% CI 59.2, 74.8) vs. 24.6 (95% CI, 19.0, 30.2) per 1,000 patient-years, in type 2 diabetes and type 1 diabetes, respectively. Unadjusted risk for death was greater for type 2 diabetes patients (HR 3.423; 95% CI, 2.501, 4.683; p<0.0001), but the difference did not persist after adjustment for age (HRage-adj 0.859; 95% CI 0.581, 1.269; p=0.445). The incidence rate of ESRD was 18.4 (95% CI 14.2, 22.5) vs. 47.1 (95%CI 38.4, 55.9) per 1,000 patient-years, in type 2 diabetes and type 1 diabetes, respectively. Unadjusted risk for ESRD was lower in type 2 diabetes (HR 0.399; 95% CI 0.287, 0.554; p<0.0001), but the difference did not persist after adjustment for sex, age and baseline serum creatinine (HRadj 0.989; 95% CI 0.597, 1.639; p=0.965). In a mixed linear model, eGFR decline was not significantly different in type 2 vs. type 1 diabetes (difference in slope −0.19 [0.28] ml min(−1) 1.73 m(−2) year(−1); p=0.512). CONCLUSIONS/
interpretationIn diabetic nephropathy, once baseline risk factors were taken into account the risk for death, ESRD and renal function decline did not significantly differ between type 1 diabetes and type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.